Recently, a symposium has been held relating to Phase II “cancer new drug treatment” (hereinafter referred to as “PENAO” new drug project), a collaboration between Beroni and UNSW. Jacky Zhang, chairman of Beroni, and Peter Wong, CFO, attended the meeting as representatives of Beroni. To date, this project has progressed smoothly and three clinical trial sites have been identified. It is expected thatpatient recruitment will start as early as next year.
Prof Philip Hogg, Chief Research Officer and Director of Lowy Cancer Centre (UNSW) reported on the clinical progress of this project. Experimental results show that PENAO has promising anti-tumour effect.
Besides project progress update, delegates from both parties have an explicit future plan, which includes updates on experimental results, agreements regarding drug manufacturing, recruitment and HR management of an operation manager. According to the plan, Phase II will start in the second half of 2019 and will last 18-24 months.
Personnel who are involved in “PENAO new drug” will perform real-time monitoring of the progress of these three clinical trial sites in Sydney. If necessary, it is planned to include more sites to expedite the clinical trial process. To date, Beroni group has established a deep collaboration with Japanese biomedical R&D institutes and hospital and this collaboration (between Beroni and JP) will provide a comprehensive professional support to PENAO project. PENAO carries a huge market potential. Once the Sydney trial sites are established, Beroni group plans to initiate the second batch of trial sites in Japan to accelerate the translation in Japan and to facilitate patent registration to boost the innovation capability of Beroni group.